Published on
February 23, 2026
- 11:00 GMT
Pairidex Secures Lead Investment from BioGenerator Ventures for the Launch of New Highly Sensitive MRD Test for Leukemia
Reducing Uncertainty in the Care and Treatment of Blood Cancer ST. LOUIS, MO, UNITED STATES, February 23, 2026 /EINPresswire.com/ -- Pairidex, an emerging leader in leukemia detection, today announced a lead investment from BioGenerator Ventures that …
Distribution channels:
Healthcare & Pharmaceuticals Industry
...
